Kura Oncology KURA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$294.57M-62.0% | -$278.67M-60.2% | -$216.88M-9.8% | -$197.17M-8.5% | -$181.89M-8.2% | ||
| $1.15M+34.0% | $1.03M+21.7% | $833K-2.9% | $877K+1.3% | $855K-2.5% | ||
| $37.68M+13.4% | $37.11M+9.5% | $34.39M+6.0% | $31.75M+1.8% | $33.23M+11.7% | ||
| $488K-8.6% | $515K-1.5% | $552K+10.0% | $545K+11.2% | $534K+10.3% | ||
| —— | —— | —— | —— | $48.23M+9,265% | ||
| $739.75K+616% | $413K— | $309.75K— | $206.5K— | $103.25K— | ||
| —— | —— | —— | —— | $4.64M— | ||
| —— | —— | —— | —— | $4.01M-68.3% | ||
| —— | —— | $26.32M+1,284% | $15.68M+974% | $5.7M— | ||
| $988K+16.5% | $1.04M+37.6% | $1.16M+98.3% | $1.07M+166% | $848K+189% | ||
| $162.51M-33.2% | $206.55M-25.8% | $119.8M-42.6% | $173.68M+24.9% | $243.23M+250% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $87.8M+152% | $124.99M+181% | $111.23M+181% | ||
| $6.47M+852% | $6.64M+1,306% | $4.69M+3,942% | $2.12M+1,460% | $680K+215% | ||
| $664.48M-9.3% | $761.59M+15.6% | $762.4M+46.4% | $685.63M+22.1% | $732.7M+45.8% | ||
| $735.03M+17.5% | $755.13M+35.3% | $723.63M+39.6% | $595.86M+15.2% | $625.72M+49.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.72M-72.2% | $1.79M-79.2% | $1.47M-82.7% | $3.67M-42.4% | $6.19M— | ||
| —— | —— | —— | —— | —— | ||
| $1.72M-72.2% | $1.79M-98.8% | $1.46M-99.1% | $3.67M-97.6% | $6.19M— | ||
| —— | —— | —— | —— | $9.76M— | ||
| $6.73M-46.3% | $8.49M-35.4% | $9.99M-23.1% | $11.5M-7.5% | $12.53M+13.9% | ||
| $488K-8.6% | $515K-1.5% | $552K+10.0% | $545K+11.2% | $534K+10.3% | ||
| $1.15M+34.0% | $1.03M+21.7% | $833K-2.9% | $877K+1.3% | $855K-2.5% | ||
| —— | —— | —— | —— | $4.01M-68.3% | ||
| —— | —— | —— | —— | —— | ||
| $3.92M— | $6.36M— | $5.12M— | —— | —— | ||
| $988K+16.5% | $1.04M+37.6% | $1.16M+98.3% | $1.07M+166% | $848K+189% | ||
| —— | —— | $26.32M+1,284% | $15.68M+974% | $5.7M— | ||
| $664.48M-9.3% | $761.59M+15.6% | $762.4M+46.4% | $685.63M+22.1% | $732.7M+45.8% | ||
| $735.03M+17.5% | $755.13M+35.3% | $723.63M+39.6% | $595.86M+15.2% | $625.72M+49.3% | ||
| $1.72M-72.2% | $1.79M-79.2% | $1.47M-82.7% | $3.67M-42.4% | $6.19M— | ||
| $162.51M-33.2% | $206.55M-25.8% | $119.8M-42.6% | $173.68M+24.9% | $243.23M+250% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $83.11M+149% | $122.87M+179% | $110.55M+180% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kura Oncology generate?
- Kura Oncology (KURA) generated -$267.2M in operating cash flow over the trailing twelve months.
- What is Kura Oncology's free cash flow?
- After $6.5M of capital expenditures, Kura Oncology's free cash flow was -$271.6M over the trailing twelve months, down 302.9% year over year.
- Where does Kura Oncology's cash flow data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
